Psychedelic medicine: mechanisms, evidence, and translation to practice.

This state-of-the-art review examines the evidence for these treatments and their proposed mechanisms of action, and identifies key challenges in clinical translation.

这篇最新的综述检查了这些治疗方法及其作用机制的证据，并确定了临床转化中的关键挑战。

Psychedelic treatments combine limited drug administration with psychotherapy or psychological support, potentially working through various biological and psychological pathways, including effects on neural circuitry, emotional processing, and psychological flexibility, though the precise mechanisms are not completely understood.

迷幻药物治疗结合有限的药物使用与心理治疗或心理支持，可能通过多种生物学和心理学途径发挥作用，包括对神经回路、情感处理和心理灵活性的影响，尽管其精确机制尚未完全明确。

The strongest evidence supports psilocybin for treatment resistant depression and MDMA for post-traumatic stress disorder, with emerging data in substance use disorders and psychological distress in life threatening illness.

最强的证据支持使用赛洛西宾治疗难治性抑郁症和使用MDMA治疗创伤后应激障碍，同时在物质使用障碍和生命威胁性疾病的患者心理困扰方面有新的数据出现。

Although psychedelics are well tolerated under controlled conditions, methodological limitations complicate interpretation of the evidence, including functional unblinding, variable psychotherapeutic protocols, and homogeneous trial populations.

尽管在受控条件下迷幻药的耐受性良好，但方法学上的局限性使得证据解释复杂化，包括功能上的非盲法、可变的心理治疗方案以及同质化的试验人群。

Current treatment models require extensive therapeutic support in specialized settings, posing challenges with scalability.

当前的治疗模式需要在专业设置中进行广泛的治疗支持，这给可扩展性带来了挑战。

While innovative approaches like group administration may improve accessibility, their comparative effectiveness remains to be established.

尽管像团体给药这样的创新方法可能会提高可及性，但其相对有效性仍需进一步确立。

Future priorities for the research field include standardizing adverse eventassessment, developing evidence based implementation guidelines, and showing durable benefit in diverse patient populations.

未来研究领域的主要优先事项包括标准化不良事件评估、制定基于证据的实施指南，并在不同患者群体中展示持久的益处。

Whether psychedelic treatments can fulfil their therapeutic promise while meeting regulatory requirements and healthcare system constraints remains a defining question for the field.

迷幻药物治疗是否能在满足监管要求和医疗体系限制的同时实现其治疗潜力，仍是该领域的一个关键问题。